Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) has issued an announcement.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has announced the composition of its board of directors and their respective roles within the company. This announcement includes the appointment of executive and independent non-executive directors, as well as the allocation of roles within the company’s four board committees, which are crucial for strategic decision-making and governance.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a pharmaceutical company based in China, focusing on the development, production, and sale of heparin and other related products. The company operates in the pharmaceutical industry, providing essential medical products to various markets.
YTD Price Performance: 15.66%
Average Trading Volume: 3,120,635
Technical Sentiment Signal: Sell
Current Market Cap: HK$16.43B
For detailed information about 9989 stock, go to TipRanks’ Stock Analysis page.